RC
BKYI

RegentAtlantic Capital’s BIO-key International BKYI Stock Holding History

RegentAtlantic Capital’s Portfolio BKYI Stock Details BKYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7
Closed -$4K – 507
2020
Q3 		$4K Buy
+7
New +$6.61K ﹤0.01% 492

Other funds holding BKYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MML Investors Services
MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

RegentAtlantic Capital's BKYI Position: Q4 2020 in Review

RegentAtlantic Capital sold out of BIO-key International (BKYI) in Q4 2020, closing a stake of 7 shares — an estimated $4K sold.

RegentAtlantic Capital first reported a position in BKYI in Q3 2020 and held it in 1 quarter. The position peaked at $4K in Q3 2020. 12 funds tracked by Wall St. Rank hold BKYI as of Q4 2020.

  • RegentAtlantic Capital reported no remaining BIO-key International position as of Q4 2020 after selling out during the quarter.
  • RegentAtlantic Capital sold 7 BIO-key International shares in Q4 2020, an estimated $4K.
  • RegentAtlantic Capital first reported a position in BIO-key International in Q3 2020 and held it in 1 quarter.
  • RegentAtlantic Capital's BIO-key International position peaked at $4K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held BIO-key International as of Q4 2020.

Based on RegentAtlantic Capital's 13F filing for Q4 2020, filed 4 Feb 2021.